Trial · NCT05155189
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | TEAEs | start pretreatment to 12 months | treatment emergent adverse events |
| Primary | AESIs | start pretreatment to 12 months | adverse events of special interest |
| Secondary | objective response rate by RECIST 1.1 | at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion | objective response rate according to RECIST 1.1 |
| Secondary | disease control rate by RECIST 1.1 | at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion | disease control rate according to RECIST 1.1 |
| Secondary | duration of response by RECIST 1.1 | at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion | duration of response according to RECIST 1.1 |
| Secondary | progression-free survival by RECIST 1.1 | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | progression-free survival to RECIST 1.1 |
| Secondary | objective response rate by mRECIST | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | objective response rate according to mRECIST |
| Secondary | disease control rate by RECIST | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | disease control rate according to mRECIST |
| Secondary | duration of response by mRECIST | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | duration of response according to mRECIST |
| Secondary | progression-free survival by mRECIST | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | progression-free survival to mRECIST |
| Secondary | overall survival | start pretreatment to the date of deaths | overall survival |
| Secondary | 6-months overall survival | start pretreatment to 6 months after cell infusion | 6-months overall survival |
| Secondary | 12-months overall survival | start pretreatment to 12 months after cell infusion | 12-months overall survival |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05155189/registered